Northern Trust’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.21M | Buy |
150,887
+127,175
| +536% | +$3.02M | ﹤0.01% | 2883 |
|
|
2026
Q1 | $614K | Sell |
23,712
-1,729
| -7% | -$49.8K | ﹤0.01% | 3532 |
|
|
2025
Q4 | $694K | Buy |
25,441
+2,156
| +9% | +$37.8K | ﹤0.01% | 3536 |
|
|
2025
Q3 | $349K | Buy |
+23,285
| New | +$268K | ﹤0.01% | 3779 |
|
|
2024
Q3 | – | Sell |
-1,073
| Closed | -$14.4K | – | 4424 |
|
|
2024
Q2 | $14.4K | Sell |
1,073
-3
| -0.3% | -$48 | ﹤0.01% | 4354 |
|
|
2024
Q1 | $18.7K | Hold |
1,076
| – | – | ﹤0.01% | 4341 |
|
|
2023
Q4 | $22.1K | Hold |
1,076
| – | – | ﹤0.01% | 4353 |
|
|
2023
Q3 | $17.8K | Sell |
1,076
-269
| -20% | -$5.96K | ﹤0.01% | 4348 |
|
|
2023
Q2 | $35K | Buy |
1,345
+269
| +25% | +$6.99K | ﹤0.01% | 4301 |
|
|
2023
Q1 | $27.2K | Buy |
1,076
+21
| +2% | +$528 | ﹤0.01% | 4392 |
|
|
2022
Q4 | $26.4K | Hold |
1,055
| – | – | ﹤0.01% | 4426 |
|
|
2022
Q3 | $28K | Buy |
1,055
+264
| +33% | +$8.39K | ﹤0.01% | 4476 |
|
|
2022
Q2 | $26K | Sell |
791
-3,341
| -81% | -$106K | ﹤0.01% | 4578 |
|
|
2022
Q1 | $151K | Sell |
4,132
-104
| -2% | -$3.94K | ﹤0.01% | 4223 |
|
|
2021
Q4 | $227K | Buy |
4,236
+2
| +0% | +$135 | ﹤0.01% | 4156 |
|
|
2021
Q3 | $313K | Buy |
4,234
+2,693
| +175% | +$1.49M | ﹤0.01% | 3956 |
|
|
2021
Q2 | $1.3M | Buy |
1,541
+713
| +86% | +$642K | ﹤0.01% | 3471 |
|
|
2021
Q1 | $710K | Buy |
828
+12
| +1% | +$9.83K | ﹤0.01% | 3713 |
|
|
2020
Q4 | $743K | Buy |
816
+36
| +5% | +$33.8K | ﹤0.01% | 3615 |
|
|
2020
Q3 | $946K | Buy |
780
+619
| +384% | +$410K | ﹤0.01% | 3416 |
|
|
2020
Q2 | $59K | Sell |
161
-555
| -78% | -$248K | ﹤0.01% | 4025 |
|
|
2020
Q1 | $327K | Buy |
716
+38
| +6% | +$14.8K | ﹤0.01% | 3551 |
|
|
2019
Q4 | $136K | Sell |
678
-33
| -5% | -$7.48K | ﹤0.01% | 3876 |
|
|
2019
Q3 | $177K | Buy |
711
+91
| +15% | +$138K | ﹤0.01% | 3796 |
|
|
2019
Q2 | $1.55M | Sell |
620
-9
| -1% | -$26.7K | ﹤0.01% | 3189 |
|
|
2019
Q1 | $2.56M | Buy |
629
+34
| +6% | +$131K | ﹤0.01% | 2926 |
|
|
2018
Q4 | $1.83M | Buy |
595
+53
| +10% | +$228K | ﹤0.01% | 3107 |
|
|
2018
Q3 | $3.17M | Buy |
542
+57
| +12% | +$217K | ﹤0.01% | 2958 |
|
|
2018
Q2 | $1.7M | Hold |
485
| – | – | ﹤0.01% | 3280 |
|
|
2018
Q1 | $2.15M | Sell |
485
-26
| -5% | -$120K | ﹤0.01% | 3064 |
|
|
2017
Q4 | $1.96M | Buy |
511
+245
| +92% | +$978K | ﹤0.01% | 3150 |
|
|
2017
Q3 | $1.24M | Hold |
266
| – | – | ﹤0.01% | 3385 |
|
|
2017
Q2 | $1.2M | Buy |
+266
| New | +$1.5M | ﹤0.01% | 3393 |
|
Other funds holding FBRX
AAA
VCM
WP
IHAM
CS
Northern Trust's FBRX Position: Q2 2026 in Review
Northern Trust increased its Forte Biosciences (FBRX) stake by 536% in Q2 2026, buying an estimated $3.02M and bringing the position to 150,887 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2883.
Northern Trust first reported a position in FBRX in Q2 2017 and has held it in 33 quarters since. 57 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.
- Northern Trust held 150,887 shares of Forte Biosciences worth $3.21M as of Q2 2026.
- Northern Trust bought 127,175 Forte Biosciences shares in Q2 2026, an estimated $3.02M.
- Forte Biosciences made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2883 holding.
- Northern Trust first reported a position in Forte Biosciences in Q2 2017 and has held it in 33 quarters since.
- 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.